Non-communicable diseases
V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines
September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated […] September 20, 2023 · V-Bio VenturesV-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases
Ghent, Belgium, 7 September 2023 – Corteria Pharmaceuticals, a V-Bio Ventures portfolio company, is a biopharmaceutical company specialized in the […] September 7, 2023 · V-Bio Ventures
The obesity revolution: will new drugs bring about big changes?
The recent approval of the obesity and diabetes drugs Wegovy, Ozempic, and Mounjaro has brought about big headlines, but are […] June 21, 2023 · V-Bio Ventures
Byteflies: virtual care solutions for all
Byteflies is on a mission to make virtual care available to all. The Belgian company has developed a platform for […] May 24, 2023 · MEDVIAV-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its […] May 15, 2023 · V-Bio Ventures
Fundamental research leads to treatment breakthrough in rare genetic diseases
A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing […] June 8, 2020 · BioVox
How changing diets gave rise to the world’s deadliest diseases
In a recent article, we discussed how the most prescribed drugs are usually indicated for common noncommunicable diseases. These include […] June 8, 2020 · V-Bio Ventures
Colorectal cancer discovery raises hope for microbiome treatment
A new mechanism causing colorectal cancer has been discovered by researchers from VIB and Ghent University. A specific protein was […] July 7, 2020 · BioVox
The opioid epidemic: solutions to a painful problem
Opioid misuse is a public health crisis that has resulted in debilitation, deaths, and significant social and economic impact. The […] July 7, 2020 · V-Bio VenturesNewton Biocapital I invests in J-Pharma Co., Ltd. in Japan focusing on drug development targeting L-type Amino Acid Transporter 1 (LAT1) for cancer and autoimmune diseases
Brussels, Belgium / Tokyo, Japan – 27 August 2020 – Newton Biocapital I (“Newton”), an investment company in life sciences, […] August 27, 2020 · Quality by Design - Business & CommunicationsBiodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures
V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio Ventures
Belgian stem cell company GST bought by German pharmaceutical giant
The German pharmaceutical giant Boehringer Ingelheim has acquired GST, a stem cell specialist based in Belgium. A part of the […] August 31, 2020 · Quality by Design - Business & Communications
A novel approach to neurology could bring relief to people in pain
In August 2020, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to […] August 31, 2020 · V-Bio Ventures